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Tenosynovial giant cell tumor is a neoplastic disease of joints that can cause severe morbidity. Recurrences are common
following local therapy, and no eﬀective medical therapy currently exists. Recent work has demonstrated that all cases overexpress
macrophage colony-stimulating factor (CSF1), usually as a consequence of an activating gene translocation, resulting in an inﬂux
of macrophages that form the bulk of the tumor. New anti-CSF1 drugs have been developed; however there are no preclinical
models suitable for evaluation of drug beneﬁts in this disease. In this paper, we describe a novel renal subcapsular xenograft model
of tenosynovial giant cell tumor. Using this model, we demonstrate that an anti-CSF1 monoclonal antibody signiﬁcantly inhibits
host macrophage inﬁltration into this tumor. The results from this model support clinical trials of equivalent humanized agents
and anti-CSF1R small molecule drugs in cases of tenosynovial giant cell tumor refractory to conventional local therapy.
1.Introduction
Tenosynovial giant cell tumor (TGCT) aﬀects young adults,
and can occur as a localized soft tissue neoplasm in the
synovial lining of tendon sheaths (commonly known as giant
cell tumor of tendon sheath) or in the lining of synovial
joints, where it is commonly known as pigmented villon-
odular synovitis (PVNS) [1]. PVNS is locally aggressive,
with the capacity to invade surrounding soft tissues and
bone, erode the articular cartilage on the surface of the
joint, and eventually cause signiﬁcant morbidity through the
development of secondary arthritis. Malignant progression
of PVNS is uncommon but does occur [2]. In spite of
treatment with total synovectomy, and even with adjuvant
radiation therapy, PVNS has a high recurrence rate [1].
In most cases of tenosynovial giant cell tumor, a
disease-speciﬁc COL6A3-CSF1 translocation is detectable in
a distinct subpopulation of tumor cells. The presence of
high levels of CSF1 expression, recruiting a large body of
macrophages to the tumor site, appears to be a consistent
feature in all forms of this disease [3, 4]. Thus, aberrant
CSF1signalingplaysacriticalroleintumordevelopmentand
progression in PVNS/TGCT, which may therefore represent
the ideal index disease to test the therapeutic value of CSF1
inhibitors. The value of testing this strategy is of immediate
clinical relevance because of the current lack of eﬀective
medical therapies for this disease.
Imatinib is known to inhibit the macrophage colony-
stimulating factor receptor (CSF1R), as evidenced in a
recent dramatic report where imatinib treatment led to a
complete response in one case of advanced recurrent PVNS
[5]. However, subsequent studies have only demonstrated
stable disease (Blay; personal communication). Recruitment
of macrophages to tumor sites and regulation of their
functional specialization through CSF1 promote growth and
metastasis in many tumor types [6], and the development
of agents blocking CSF1 signaling has therefore become an
active focus of research [7, 8]. Given that imatinib is not2 Sarcoma
aparticularlystronginhibitorofCSF1R[9],itispossiblethat
other agents, including investigational new drugs speciﬁcally
designed to block CSF1 signaling, might be better choices.
The immediate problem in designing preclinical studies
for PVNS/TGCT therapies is a lack of suitable experimental
models. As might be expected in a lesion where >90%
of tumor cells are host macrophages, this disease cannot
easily be modeled in vitro, and no cell lines currently
exist. Furthermore, as with most tumors that grow slowly,
standard subcutaneous xenografts have very poor take rates.
In this study, we establish a new model for PVNS/TGCT
by transplanting primary human tumor samples under the
renal capsule of NOD SCID mice. We then develop an assay
for recruitment of host macrophages into the implanted
human tumor tissues, allowing us to test the eﬀectiveness
of imatinib and of antihuman CSF1 antibodies to block
macrophage recruitment in this model system.
2.MaterialsandMethods
2.1. Primary Tumor Tissue and Clinical Information. Eight
patients diagnosed with PVNS/TGCT requiring surgical
excision at Vancouver General Hospital were consented
for this experimental study. Volunteers were treated in
accordance with the Canadian Tri-Council Policy Statement
on the ethical conduct for research involving humans, and
these studies were reviewed and approved by the BC Cancer
Agency Research Ethics Board. Median patient age was 39.5
years, ranging from 20 to 50 years. Clinical data for these
patients is summarized in Table 1.
2.2. Renal Subcapsular Xenotransplantation. Approximately
1cc of fresh tumor tissue was obtained from each patient,
and fragments of 3×2×1mm were grafted under the kidney
capsule of 20 to 36 nonobese diabetic/severe combined
immunodeﬁciency (NOD SCID) mice. These methods are
described in detail in previous published work and have a
high rate of successful engraftment [10, 11].
Animal care and experiments were carried out in accor-
dance with the guidelines of the Canadian Council on
Animal Care and were approved by the Animal Care Com-
mittee of The University of British Columbia. Meloxicam
was administered subcutaneously prior to the surgery to
provide long-term pain relief. Animals were weighed and
anaesthetized with Ketamine/Xylazine (100 and 10mg/kg
resp., 0.1ml/25g body weight, intraperitoneal injection).
Bupivacaine was administered as local anaesthetic at the
injection site. An incision of approximately 2.5cmwasmade
along the midline of the skin in the back of the mouse. With
the animal lying on its side, a small incision was made in
the body wall with length slightly longer than the long axis
of the kidney. The kidney was then exteriorized by applying
pressureonitsothersideusingtheforeﬁngerandthumb.The
exteriorized kidney rested on the body wall. A ﬁne pair of
forceps was used to gently pinch and lift the capsule from the
parenchyma of the kidney so that a 2–4mm incision could
be made in the capsule with ﬁne spring-loaded scissors. A
pocket was created between the kidney and the parenchyma
by blunt dissection. Great care was taken not to damage the
kidney parenchyma and thus prevent bleeding. The graft was
transferred to the surface of the kidney using a blunt scalpel.
The cut edge of the kidney capsule was lifted with a pair
of ﬁne forceps and the graft was inserted into the pocket
under the capsule using a polished glass pipette. Once the
grafting procedure was completed, the kidney was gently
eased back into the body cavity; and the incision in body
wall (muscle layers) was closed with 4–0 sutures; the edges
of the back skin will be aligned and closed with the aid of
suture. Buprenorphine was injected subcutaneously at 0.05–
0.10mg/kg (0.1ml/25g body weight) at the time mice show
signs of recovery from anaesthesia.
2.3. Experimental Design. Two weeks after graft implanta-
tion,NODSCIDmicewererandomlydividedintotreatment
and control groups. For CSF1 antibody treatment, the
mouse antihuman CSF1 monoclonal antibody 5H4 (ATCC
accession HB10027), speciﬁc for human dimeric CSF1
and not cross-reactive with mouse CSF1 [12], was kindly
provided by Novartis Institutes for Biomedical Research
(Emeryville, CA, USA). 5H4 antibody was administered
via intraperitoneal injection at 10mg/kg, once per week.
Imatinib was purchased from LC Laboratories (Woburn,
M A ,U S A )a n dw a sg i v e nv i ag a v a g ea t1 0 0 m g / k g ,o n c e
per day, in ﬁve of eight cases where enough mice and
tissue were available for this additional experimental arm.
In one case, imatinib was administered at a concentration
of 200mg/kg. Aqueous vehicle (phosphate buﬀered saline
= PBS) was used as control, given intraperitoneally once
weekly. After two weeks of treatment, all mice were sacriﬁced
in a CO2 chamber; both kidneys with their tumor grafts
were removed, ﬁxed in 10% neutral buﬀered formalin, and
paraﬃn-embedded for histology, immunochemistry, and
ﬂuorescencein situ hybridization (FISH)studies. To evaluate
longer-term 5H4 treatment eﬀects, we also completed one
experiment using 7-weeks treatment.
2.4. ParaﬃnF I S H . Fluorescent in situ hybridization (FISH)
analyses for CSF1 gene disruptions were performed using
break-apart hybridization probes, using the same protocol as
previously described in [3]. For negative cases, a minimum
of 500 nuclei were assessed in the primary tumor specimen.
2.5. Histopathology and Immunohistochemistry. H&E stain-
ing was performed for histopathologic evaluation using
standard protocols. For immunohistochemistry, antigen
retrieval was performed in 0.1M citrate buﬀer (pH 6.0)
in a steamer. Endogenous peroxidase activity was blocked
with3% hydrogenperoxide,andnonspeciﬁcprotein binding
was blocked with serum-free Protein Block (Dako, Carpen-
teria, CA). Rat antimouse macrophage F4/80 monoclonal
antibody (Invitrogen Corp, Carlsbad, CA) was applied at
1:50 dilution and incubated overnight at 4◦C. Biotinylated
antirat secondary antibody (Dako, Carpenteria, CA) at
1:300 dilution was labeled with horseradish peroxidase-
conjugated streptavidin (Vector Labs, Burlingame, CA) and
visualized using Nova Red Substrate Kit (Vector Labs).Sarcoma 3
Table 1: Clinical information on the eight PVNS/TGCT cases used in this study.
Case ID Presentation Location Size (cm) Recurrent CSF1 translocation
1D i ﬀuse Knee 7 Yes +
2D i ﬀuse Knee 5 No −
3N o d u l a r K n e e 6N o +
4 Nodular Foot 4 No −
5 Nodular Finger 1.9 No +
6D i ﬀuse Knee 10 No −
7 Nodular Knee 2 No −
8D i ﬀuse Hip 6 No n/a
Mouse antihuman Ki67 monoclonal antibody SP6 (Dako,
Carpenteria, CA) at 1: 50 dilution and human macrophage
CD163 (Novocastra, Newcastle, UK) at 1:100 dilution were
applied by using the M.O.M. Kit (Vector Labs) according
to the manufacturer’s recommendations. Goat polyclonal
antihuman CSF1 (GeneTex, Irvine CA) at 1:10 dilution was
evaluated using the Vectastain Elite ABC goat Kit (Vector
Labs), with the DAB chromogen (Dako) applied for 10
minutes at room temperature.
2.6. Immunohistochemical Scoring and Statistical Analysis.
Immunohistochemical staining results were scored for the
percentage of positive cells in a section from the middle of
the whole grafted tumor area, except for human Ki67 (which
was scored for the absolute count of positive nuclei per high
power microscope ﬁeld of xenograft tissue). Because a thin
inﬂammatory layer usually exists surrounding the implanted
tumor tissues as a surgical reaction, this outer layer was
excluded from scoring for assayed markers including F4/80.
All scoring work was done by a pathologist who was blinded
to all drug treatment and sample identiﬁers; codes were only
broken after all scores were ﬁnalized, and the scoring and
data analysis were handled by separate researchers. Murine
macrophages were identiﬁed by F4/80 staining, and the host
macrophage inﬁltration index was deﬁned as the number of
F4/80 positive cells, divided by the total number of cells in
the examined whole sections from the xenografted tumor.
Results are expressed as percentages, and experimental error
is reported corresponding to the 95% conﬁdence intervals
of the observed medians. The signiﬁcance of treatment
eﬀects compared to PBS control was evaluated within each
treatment group (5H4 versus PBS and imatinib versus PBS)
using pairwise Wilcoxon rank sum tests. Foldchanges in
macrophage inﬁltration rate are reported on aggregate as
the mean fold-change across all mice within each treatment
group. 95% conﬁdence intervals of the mean foldchange
were estimated from bias-corrected accelerated bootstrap
calculations using 1000 replicates [13].
3. Results
3.1. A Renal Subcapsular Xenograft Model of Pigmented
Villonodular Synovitis/Tenosynovial Giant Cell Tumor. For
all cases, tenosynovial giant cell tumor xenografts implanted
under the renal capsule of NOD SCID mice yielded viable
human tumor tissue at sacriﬁce (at times ranging from
one to six months). Tumors did not grow appreciably in
size; the fraction of cells positive for human Ki67 was less
than 1% and was not aﬀected by drug treatment. To assess
the representativeness of the PVNS/TGCT renal subcapsular
xenografts, we examined side by side the harvested graft
tissues and their corresponding primary tumor specimens,
comparing their histomorphological features, CSF1 translo-
cation status, and CSF1 protein expression patterns.
The CSF1 translocation (Figure 1(a))w a si d e n t i ﬁ a b l e
in only three out of the eight case specimens recruited in
this study, a ﬁnding not unexpected considering that the
CSF1 translocation can only be detected in about 60% of
cases and even then in only a small minority of tumor cells
(about 2%) [3]. Histologically, all examined PVNS/TGCT
tumor grafts were very similar to their primary tumor
counterparts (Figures 1(b) and 1(c)). However, whereas a
mix of CD163+ human and F4/80+ murine macrophages
present in the grafts two weeks after implantation, by four
weeks murine host F4/80+ macrophages had replaced most
of the human macrophages, and syncytial giant cells were
rarely present. CSF1 expression exhibited an overall diﬀuse
pattern in both tumor grafts and primary tumor tissues
(Figure 1(d)), very similar to the CSF1 expression patterns
previously described in [3, 4]. Tumors were stable to the
lifespan of the NOD/SCID host (6 months) but subclones
could not be passaged into a new generation.
3.2. An Anti-CSF1 Monoclonal Antibody Signiﬁcantly Reduces
Host Macrophage Inﬁltration into PVNS/TGCT Xenografts.
Human CSF1 is known to crossreact with and stimulate
murine macrophages [8] .5 H 4i sam o u s em o n o c l o n a l
antibody that speciﬁcally neutralizes human CSF1. In short-
term in vitro culture of primary PVNS tumor tissue, 5H4
did not show any cytotoxic eﬀects (data not shown). When
administered by the intraperitoneal route to mice bearing
PVNS xenografts, 5H4 signiﬁcantly blocked murine host
macrophage recruitment to the tumor site (Figures 1(e) and
1(f)). Eﬀects of 5H4 on xenograft series derived from eight
individual patients are shown in Figure 2, in comparison
to PBS and imatinib. As scored by pathologists blinded to
treatment group, 5H4 decreased the macrophage inﬁltration
for all cases in 2-week treatment experiments, by an average
of 2.7-fold in comparison with vehicle control (PBS) (95%




Figure 1: Renal subcapsular implant model of tensosynovial giant cell tumor. (a) Fluorescence in situ hybridization on xenograft using
red and green probes ﬂanking the CSF1 locus, showing split probes in the rightmost cell, consistent with translocation of CSF1 sequences
(objective magniﬁcation 100x). ((b)-(c)) H&E histology of the xenograft: (b) host kidney on the left and tumor on the right (objective
magniﬁcation 10x); (c) centre of the xenograft (objective magniﬁcation 40x). (d) Immunohistochemistry for CSF1 in xenograft tissue
(objective magniﬁcation 20x). ((e)-(f)) F4/80 immunohistochemistry (20x objective magniﬁcation), showing host macrophage inﬁltration
in PVNS xenografts: (e) PBS control, (f) mice treated with 5H4 anti-CSF1 antibody.
treatment was continued out to 7 weeks, the fraction of host
macrophages among cells in the xenograft was 60% (95% CI
53%–67%) in the PBS arm as compared to 30% in the 5H4
arm (95% CI 24%–36%).
3.3. Imatinib Blocks Macrophage Inﬁltration to a Lesser
Extent Than 5H4 in This Renal Subcapsular Implant Model.
Since imatinib functions as a CSF1R inhibitor [9]a n d
was highly eﬀective in a PVNS clinical case report [5],
we used it as a comparative control in this study when
suﬃcient numbers of xenograft-bearing mice were available.
We tested ﬁve patients’ tissues at 100mg/kg/day imatinib,
ad o s er e p o r t e dt oe ﬀectively suppress metastases in breast
cancer xenograft models [14] and one at 200mg/kg/day
(the maximum tolerable dose in short-term treatment
[15]). Across all six experiments, imatinib decreased host
macrophage inﬁltration by 1.1-fold relative to PBS control
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Figure 2: Eﬀect of CSF1 inhibitors on macrophage inﬁltration in PVNS xenografts. (a) Data from experiments using eight individual
patient tumors (host macrophages counted after 2 weeks of the indicated treatments). Error bars represent the 95% conﬁdence interval of
the observed median. In case number eight, the dose of imatinib was doubled to 200mg/kg but showed similar eﬀects. (∗)d e n o t e sc a s e s
where imatinib was not given.
statistically signiﬁcant (Figure 2). Relative to 5H4, imatinib
showed a lesser eﬀect on reducing macrophage recruitment
at these doses in this model system. Imatinib had no
signiﬁcanteﬀectonthenumberofhumanKi67-positive cells
relative to controls (data not shown).
4. Discussion
Grafting human primary tumors beneath the renal capsule
in NOD SCID mice is a recently developed method for
the establishment of xenograft models. Relative to the
low engraftment rate seen with subcutaneous implantation
(typically 20–40% for aggressive carcinomas) [16], renal
subcapsular implantation shows a high tumor take rate
(possibly due to its high tissue perfusion environment)
and is especially advantageous for establishing models of
low-grade, slow-growing tumors [10, 11]. In our PVNS
models, the estimated engraftment rate of grossly evident,
microscopicallyconﬁrmedviabletumortissuewasover95%.
Harvested grafts maintained characteristic features of the
original tumors with respect to tumor morphology, CSF1
translocation status, CSF1, and macrophage CD163 expres-
sion, making this the ﬁrst PVNS model of practical use for
preclinicaltherapeuticinvestigation.Althoughtheimplanted
tumors did not grow appreciably in net size, we could
assess the inﬁltration of F4/80+ host murine macrophages.
In experiments using other tumor types which do not
produce CSF1 (synovial sarcoma, clear cell sarcoma, and
myxoid liposarcoma), no host F4/80+ macrophage inﬁltrates
were seen (Cheng and Nielsen, unpublished observations),
supporting that their presence in PVNS xenografts indeed
occurs as a consequence of tumor CSF1 expression rather
than as a reaction to the implantation procedure. This model
can be used to test the eﬀects of a new generation of
drug agents designed to block CSF1-recruited macrophage
inﬁltration.
Tumor-derived CSF1 overexpression is a common
ﬁnding in many types of human neoplasms [17, 18].
In conjunction with well-recognized roles in stimulating
macrophage survival, proliferation, and diﬀerentiation [19],
CSF1 appears to direct macrophages to adopt an M2 pheno-
type [20]. This macrophage subtype is involved in immune
regulation,woundhealing,andsecondarilyintumorpromo-
tion, rather than in active phagocytic antipathogen immune
responses. Intratumoral macrophage inﬁltration is seen in
clinical and experimental studies of many tumor types and
correlates with poor tumor prognosis, for example, in can-
cers of breast, prostate, ovary, and smooth muscle [20–23].
The mechanisms by which tumor associated macrophages
are thought to promote tumor growth include roles in
supporting angiogenesis, secretion of tumor growth factors,
suppression of immunosurveillance, and enhancement of
tumor metastasis [6, 24]. Thus accumulating evidence indi-
cates a potentially important role of CSF1 signaling in cancer
biology, and many anti-CSF1 approaches are currently
being developed. For example, CSF1 antibody, antisense
oligonucleotide, and CSF1 small interfering RNA strategies
have all demonstrated tumor suppression capabilities to
various degrees in other disease and model systems [7, 8].
Since CSF1-activating translocation-driven macrophage
recruitment is fundamental to the pathophysiology of PVNS
[3, 4], this neoplasm plausibly represents an index disease
model for assessing the value of anti-CSF1 therapeutics. In
study, we tested the eﬀect of 5H4, a mouse monoclonal
antihuman CSF1-neutralizing antibody, for its ability to
inhibit macrophage recruitment in our PVNS xenograft
model. Based on the anti-CSF1 receptor activity of imatinib
[9, 14, 25, 26] and a recent publication showing imatinib’s
therapeutic eﬀects in one PVNS case [5], we chose imatinib
as a positive control in our experiments. Relative to 5H4,
imatinib exhibited a lesser macrophage blockade eﬀect
in the animal model at the doses employed (100 and6 Sarcoma
200mg/kg). The target in this model system is host murine
CSF1R, rather than human CSF1R, which could result in an
underestimation of the beneﬁt of imatinib; of note, recent
studies have nevertheless proven that imatinib does inhibit
phosphorylation of murine CSF1R [14].
5. Conclusions
ThisstudyintroducesandcharacterizesaPVNSmodelwhich
is suitable for anti-CSF1 therapeutic studies. We were able
todemonstratethatanti-CSF1therapiesimpedemacrophage
recruitment, supporting their potential value as therapeutic
agents in this locally aggressive disease of joints for which no
established, eﬀective drug therapy currently exists.
Abbreviations
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PVNS: Pigmented villonodular synovitis
TGCT: Tenosynovial giant cell tumor.
Acknowledgments
T.O. Nielsen is a Senior Scholar of the Michael Smith
Foundation for Health Research. This work, initiated using
pilot funds from the Sarcoma Foundation of America, was
supported by an operating grant from The Cancer Research
Society. The authors thank Samuel Leung and Neal Poulin
for assistance in data analysis and manuscript preparation
and Robert B. West and Kelli Montgomery (Stanford Univer-
sity)foradviceonCSF1immunohistochemistry.Theyreport
no ﬁnancial interest in the results of this study.
References
[1] V. Sharma and E. Y. Cheng, “Outcomes after excision
of pigmented villonodular synovitis of the knee,” Clinical
Orthopaedics and Related Research, vol. 467, no. 11, pp. 2852–
2858, 2009.
[2] L. J. Layﬁeld, A. Meloni-Ehrig, K. Liu, R. Shepard, and J. M.
Harrelson, “Malignant giant cell tumor of synovium (malig-
nant pigmented villonodular synovitis): a histopathologic and
ﬂuorescence in situ hybridization analysis of 2 cases with
review of the literature,” Archives of Pathology and Laboratory
Medicine, vol. 124, no. 11, pp. 1636–1641, 2000.
[3] R. B. West, B. P. Rubin, M. A. Miller et al., “A landscape
eﬀectintenosynovialgiant-celltumorfromactivationofCSF1
expression by a translocation in a minority of tumor cells,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 103, no. 3, pp. 690–695, 2006.
[ 4 ]J .S .C u p p ,M .A .M i l l e r ,K .D .M o n t g o m e r ye ta l . ,“ T r a n s l o -
cation and expression of CSF1 in pigmented villonodular
synovitis, tenosynovial giant cell tumor, rheumatoid arthritis
and other reactive synovitides,” American Journal of Surgical
Pathology, vol. 31, no. 6, pp. 970–976, 2007.
[5] J.-Y. Blay, H. El Sayadi, P. Thiesse, J. Garret, and I. Ray-
Coquard, “Complete response to imatinib in relapsing pig-
mented villonodular synovitis/tenosynovial giant cell tumor
(PVNS/TGCT),” Annals of Oncology, vol. 19, no. 4, pp. 821–
822, 2008.
[6] K. S. Siveen and G. Kuttan, “Role of macrophages in tumour
progression,” Immunology Letters, vol. 123, no. 2, pp. 97–102,
2009.
[7] P. Paulus, E. R. Stanley, R. Sch¨ afer, D. Abraham, and S.
Aharinejad, “Colony-stimulating factor-1 antibody reverses
chemoresistance in human MCF-7 breast cancer xenografts,”
Cancer Research, vol. 66, no. 8, pp. 4349–4356, 2006.
[8] S. Aharinejad, P. Paulus, M. Sioud et al., “Colony-stimulating
factor-1 blockade by antisense oligonucleotides and small
interfering RNAs suppresses growth of human mammary
tumor xenografts in mice,” Cancer Research, vol. 64, no. 15,
pp. 5378–5384, 2004.
[ 9 ]A .L .D e w a r ,A .C .C a m b a r e r i ,A .C .W .Z a n n e t t i n oe ta l . ,
“Macrophage colony-stimulating factor receptor c-fms is a
noveltargetofimatinib,”Blood,vol.105,no.8,pp.3127–3132,
2005.
[10] Y. Wang, M. P. Revelo, D. Sudilovsky et al., “Development and
characterization of eﬃcient xenograft models for benign and
malignant human prostate tissue,” Prostate,v o l .6 4 ,n o .2 ,p p .
149–159, 2005.
[11] J.-C. Cutz, J. Guan, J. Bayani et al., “Establishment in
severe combined immunodeﬁciency mice of subrenal capsule
xenografts and transplantable tumor lines from a variety of
primary human lung cancers: potential models for studying
tumor progression-related changes,” Clinical Cancer Research,
vol. 12, no. 13, pp. 4043–4054, 2006.
[12] D. L. Zimmerman, G. Harrowe, L. Cheng et al., “Methods
for preventing and treating cancer metastasis and bone loss
associated with cancer metastasis,” European patent number:
EP1572106(B1), European Patent Oﬃce, Assignee: Novartis
Vaccines and Diagnostics, Inc., Belgium, 2010.
[13] B.Efron,“Betterbootstrapconﬁdenceintervals,”Journalofthe
American Statistical Association, vol. 82, no. 397, pp. 171–185,
1987.
[14] T. Hiraga and H. Nakamura, “Imatinib mesylate suppresses
bone metastases of breast cancer by inhibiting osteoclasts
through the blockade of c-Fms signals,” International Journal
of Cancer, vol. 124, no. 1, pp. 215–222, 2009.
[15] R. Kerkel¨ a, L. Grazette, R. Yacobi et al., “Cardiotoxicity of the
cancer therapeutic agent imatinib mesylate,” Nature Medicine,
vol. 12, no. 8, pp. 908–916, 2006.
[ 1 6 ] I .F i c h t n e r ,J .R o l ﬀ, R. Soong et al., “Establishment of patient-
derived non-small cell lung cancer xenografts as models for
the identiﬁcation of predictive biomarkers,” Clinical Cancer
Research, vol. 14, no. 20, pp. 6456–6468, 2008.
[17] E. Richardsen, R. D. Uglehus, J. Due, C. Busch, and L.-T. R.
Busund, “The prognostic impact of M-CSF, CSF-1 receptor,
CD68 and CD3 in prostatic carcinoma,” Histopathology, vol.
53, no. 1, pp. 30–38, 2008.
[18] I. Espinosa, A. H. Beck, C.-H. Lee et al., “Coordinate expres-
sion of colony-stimulating factor-1 and colony-stimulating
factor-1-related proteins is associated with poor prognosis in
gynecological and nongynecological leiomyosarcoma,” Amer-
ican Journal of Pathology, vol. 174, no. 6, pp. 2347–2356, 2009.
[19] M. J. Sweet and D. A. Hume, “CSF-1 as a regulator of
macrophage activation and immune responses,” Archivum
Immunologiae et Therapiae Experimentalis,v o l .5 1 ,n o .3 ,p p .
169–177, 2003.Sarcoma 7
[20] K. Kawamura, Y. Komohara, K. Takaishi, H. Katabuchi, and
M. Takeya, “Detection of M2 macrophages and colony-
stimulating factor 1expression in serous and mucinous ovar-
ian epithelial tumors,” Pathology International, vol. 59, no. 5,
pp. 300–305, 2009.
[21] R. D. Leek, R. J. Landers, A. L. Harris, and C. E. Lewis,
“Necrosis correlates with high vascular density and focal
macrophage inﬁltration in invasive carcinoma of the breast,”
British Journal of Cancer, vol. 79, no. 5-6, pp. 991–995, 1999.
[22] I. F. Lissbrant, P. Stattin, P. Wikstrom, J. E. Damber, L. Egevad,
and A. Bergh, “Tumor associated macrophages in human
prostate cancer: relation to clinicopathological variables and
survival,” International Journal of Oncology,v o l .1 7 ,n o .3 ,p p .
445–451, 2000.
[23] C.-H. Lee, I. Espinosa, S. Vrijaldenhoven et al., “Prognostic
signiﬁcance of macrophage inﬁltration in leiomyosarcomas,”
Clinical Cancer Research, vol. 14, no. 5, pp. 1423–1430, 2008.
[24] B. Al-Sarireh and O. Eremin, “Tumour-associated macro-
phages (TAMS): disordered function, immune suppression
and progressive tumour growth,” Journal of the Royal College
of Surgeons of Edinburgh, vol. 45, no. 1, pp. 1–16, 2000.
[25] N. Brownlow, A. E. Russell, H. Saravanapavan et al., “Com-
parison of nilotinib and imatinib inhibition of FMS receptor
signaling, macrophage production and osteoclastogenesis,”
Leukemia, vol. 22, no. 3, pp. 649–652, 2008.
[26] J. R. Taylor, N. Brownlow, J. Domin, and N. J. Dibb, “FMS
receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor
imatinib and mutation of Asp-802 to Val confers resistance,”
Oncogene, vol. 25, no. 1, pp. 147–151, 2006.